REVVITY Business Summary

Revvity, Inc. (RVTY) operates as a specialized health science solutions provider, generating revenue through two primary segments: Life Sciences and Diagnostics. Its business model relies on a combination of high-volume consumable sales (reagents, assays), capital equipment (imaging and detection instruments), and recurring high-margin revenue from its "Signals" informatics software platform via subscription and licensing fees. The Life Sciences segment facilitates drug discovery and translation, while the Diagnostics arm focuses on immunodiagnostics, genomics, and neonatal screening. Revvity competes directly with Thermo Fisher Scientific, Agilent Technologies, Danaher, and Bruker. Positioned as a high-growth "pure-play" entity following its 2023 divestiture of non-core industrial assets, Revvity occupies a premium niche in the market by integrating multi-omics technologies with advanced clinical workflows to accelerate the discovery-to-cure pipeline. The leadership team is anchored by President and CEO Prahlad Singh, PhD, who previously led PerkinElmer and holds a deep background in chemistry and executive management from GE Healthcare. Key executives include Senior Vice President and CFO Max Krakowiak, who oversees global finance, and Chief Scientific Officer Madhuri Hegde, PhD, a diplomat of the American Board of Medical Genetics and Genomics. Technical innovation is driven by James Maniscalco, CTO of Revvity Signals, while global operations are managed by SVP Tajinder Vohra. The company’s governance is led by Non-Executive Chair Alexis P. Michas, Managing Partner of Juniper Investment Company. Revvity is heavily backed by institutional heavyweights, with T. Rowe Price, Vanguard Group, and BlackRock serving as its largest shareholders, reflecting strong market confidence in the firm’s post-rebrand strategic pivot.